Pharmacogenetics Committee

Last Update: March 2012

Chair: R. Van Schaik (r.vanschaik@erasmusmc.nl)

Vice chair: Vincent Haufroid (mailto:vincenthaufroid@uclouvain.be)

Background/Purpose of the Committee
• To promote the knowledge, understanding and implementation of pharmacogenetics among scientists, laboratory and clinicians.

Committee Membership List
Chair: Dr. Ron van Schaik, Clinical Chemist – Erasmus University Medical Hospital
Vice-chair: Dr. Vincent Haufroid, Cliniques universitaires Saint-Luc – UCL, Laboratory of Analytical Biochemistry & Louvain center for Toxicology and Applied Pharmacology (LTAP), Bruxelles.
Members: R. Van Schaik, V. Haufroid, T. Van Gelder, M. Linder, W. Steimer, I. McPhee, P. Marquet.

Members who would like to get actively involved in one of these projects or other members who would like to propose new projects are very welcome!

Minutes of the Pharmacogenetics Committee Meeting at the Stuttgart IATDMCT Congress (on October 4, 2011):

The meeting of the PGx committee was well attented, with many new participants.Vincent Haufroid was officially introduced as vice-chair of this committee. The meeting started of with a brief survey on how far clinical implementation of pharmacogenetic testing was at the different institutes. Remarkably, and in contrast to expectations of chair and vice-chair, many PGx tests seem already to be available for routine diagnostics (with an average of 8 tests per institute). The chair proposed to organize an official survey among IATDMCT members to get an idea about the implementation of PGx testing for patient care. Next, it was discussed if IATDMCT should provide their own guidelines for PGx testing, or that we would choose to screen guidelines prepared by others (for example CPIC) and then provide an IATDMCT approval. It was mentioned that perhaps on immunosuppressives, IATDMCT has in fact the most knowledge about PGx testing, and thus would qualify best to come up with specific guidelines on this topic. The meeting did not reach a final conclusion on this. Proposed was to have a look at guidelines currently published, and discuss within the PGx committee.

Committee initiatives for 2011/2012.
• Conducting a survey about implementation of PGx testing
• Evaluate if IATDMCT can provide guidelines for PGx testing
• Providing input for the pharmacogenetics program for Stuttgart

Biomarkers Working Group (BWG)/ISD and PGx Committee meeting.
Report from a Round Table Meeting held in Barcelona March 2009